Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Investigated effect 5: Whole-body metabolic markers in obesity models
At this time, it is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027, pending further action from CMS to implement the BALANCE Model in Medicare Part D in 2028, as described below
The anti-obesity effects were confirmed in several clinical trials performed (3)
Molecular structure of DPP-4 Initially described by Hopsu-Havu & Glenner in 1966 [25], DPP-4 is a dimeric 240-kDa glycoprotein composed of two 120-kDa subunits and encoded by a gene located in chromosome 2q24 [25]
Purity: 98% (HPLC)
US$ 28.25
US$ 26.83
US$ 24.95
